相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Medicine, General & Internal
Christopher H. van Dyck et al.
Summary: Lecanemab, a humanized monoclonal antibody, reduced amyloid markers and showed improvement in cognition and function in early Alzheimer's disease patients. However, it also resulted in adverse events. Longer trials are needed to determine its efficacy and safety in early Alzheimer's disease.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
John R. Sims et al.
Summary: This study evaluated the efficacy and adverse events of donanemab, an antibody treatment for Alzheimer's disease. The findings showed that donanemab significantly slowed disease progression in patients with early symptomatic Alzheimer's disease.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Medicine, General & Internal
Reisa A. Sperling et al.
Summary: This study tested the monoclonal antibody solanezumab in treating individuals with preclinical Alzheimer's disease, but it did not show any benefit in slowing cognitive decline compared to placebo over a period of 240 weeks.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
John R. Sims et al.
Summary: This study assessed the efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque. The results showed that donanemab significantly slowed the clinical progression in individuals with early symptomatic Alzheimer disease and low/medium tau pathology, as well as in the combined population with low/medium and high tau pathology.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Cell Biology
Wiesje M. van der Flier et al.
Summary: Alzheimer's disease is a significant healthcare challenge with no current cure. This perspective proposes a strategy to shift the focus towards the pre-dementia stages and invest in personalized medicine for diagnosis, prediction and prevention. It suggests empowering patients and the public to actively participate in managing their health and disease, and developing improved strategies for early intervention.
Article
Clinical Neurology
Roos J. Jutten et al.
Summary: This study found that individuals with early AD exhibit heterogeneity in disease progression, which is further increased when stratifying based on risk factors associated with progression. Guidance for a priori effect sizes on cognitive outcomes is provided to aid in detecting true change in future AD trials.
Article
Medicine, General & Internal
Lawrence S. Honig et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2018)
Article
Medicine, General & Internal
Michael C. Donohue et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2017)
